Print Page   |   Contact Us   |   Sign In   |   Join Today
News & Press: Company News

CEL-SCI Receives European Patent for Multikine

Monday, July 18, 2016  
Share |
CEL-SCI has been granted a new European patent covering its investigational Phase 3 cancer immunotherapy drug Multikine* (Leucocyte Interleukin). The patent, titled “A Method Of Pre-Sensitizing Cancer Prior To Treatment With Radiation and/or Chemotherapy And A Novel Cytokine Mixture,” is not limited to any one particular type of cancer and can include multiple types of cancer.

This invention relates to a novel method for pre-sensitizing cancer cells prior to a therapeutic treatment such as chemotherapy or radiation therapy. This effect is created by CEL-SCI’s immunotherapy drug Multikine which, as part of its mode of action, induces cancerous cells to enter a proliferative cell cycle phase therapy, thereby potentially increasing their vulnerability to chemotherapy and radiation therapy.

Geert Kersten, Chief Executive Officer of CEL-SCI, said, “This European patent should protect one of the largest applications for Multikine, namely its use in combination with radiation and chemotherapy. Our ongoing Phase 3 clinical trial in head and neck cancer patients is administering Multikine therapy as part of a first-line treatment, before any other treatments and prior to surgery, followed by radiation or concurrent chemoradiotherapy.”

more Events

Helping Businesses Grow with Access to Government Funding Opportunities

Annual MHSRS Webinar

Premium Members

Membership Software Powered by YourMembership  ::  Legal